BC
BHVN

Broadfin Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Broadfin Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$32.7M Buy
600,000
+100,000
+20% +$4.95M 4.37% 4
2019
Q3 		$20.9M Buy
500,000
+100,000
+25% +$4.22M 3.86% 5
2019
Q2 		$17.5M Buy
+400,000
New +$22.5M 3.81% 10

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Broadfin Capital's BHVN Position: Q4 2019 in Review

Broadfin Capital reduced its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stake by 23% in Q4 2019, selling an estimated $6.1M and leaving 409,338 shares worth $22.3M. The position accounts for 2.98% of the portfolio, ranked #8.

Broadfin Capital first reported a position in BHVN in Q4 2018 and has held it in 5 quarters since. The position peaked at $29.6M in Q2 2019. 188 funds tracked by Wall St. Rank hold BHVN as of Q4 2019.

  • Broadfin Capital held 409,338 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $22.3M as of Q4 2019.
  • Broadfin Capital sold 123,253 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2019, an estimated $6.1M.
  • Biohaven Pharmaceutical Holding Company Ltd. made up 2.98% of Broadfin Capital's portfolio in Q4 2019, its #8 holding.
  • Broadfin Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and has held it in 5 quarters since.
  • Broadfin Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $29.6M in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.